AU2001244354A1 - Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for thetreatment of neurological disorders - Google Patents
Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for thetreatment of neurological disordersInfo
- Publication number
- AU2001244354A1 AU2001244354A1 AU2001244354A AU4435401A AU2001244354A1 AU 2001244354 A1 AU2001244354 A1 AU 2001244354A1 AU 2001244354 A AU2001244354 A AU 2001244354A AU 4435401 A AU4435401 A AU 4435401A AU 2001244354 A1 AU2001244354 A1 AU 2001244354A1
- Authority
- AU
- Australia
- Prior art keywords
- thetreatment
- antagonists
- gene therapy
- retinoic acid
- neurological disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
- 102000003702 retinoic acid receptors Human genes 0.000 title 1
- 108090000064 retinoic acid receptors Proteins 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000014511 neuron projection development Effects 0.000 abstract 1
- 108010079850 retinoic acid receptor beta Proteins 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
WOGB00/01211 | 2000-03-30 | ||
PCT/GB2000/001211 WO2000057900A2 (en) | 1999-03-31 | 2000-03-30 | Factor for regulation of neurite growth |
GBGB0024300.6A GB0024300D0 (en) | 2000-03-30 | 2000-10-04 | Factor |
GB0024300 | 2000-10-04 | ||
PCT/GB2001/001478 WO2001075135A1 (en) | 2000-03-30 | 2001-03-30 | Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for the treatment of neurological disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001244354A1 true AU2001244354A1 (en) | 2001-10-15 |
Family
ID=26243429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001244354A Abandoned AU2001244354A1 (en) | 2000-03-30 | 2001-03-30 | Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for thetreatment of neurological disorders |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1268835B1 (de) |
JP (1) | JP2003533184A (de) |
AT (1) | ATE384133T1 (de) |
AU (1) | AU2001244354A1 (de) |
CA (1) | CA2399399A1 (de) |
DE (1) | DE60132436T2 (de) |
WO (1) | WO2001075135A1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004069269A1 (en) * | 2003-01-30 | 2004-08-19 | Neurologix, Inc. | Method for making a cell more susceptible for a compound by expressing the protein, on which said compound acts, in said cell |
WO2005114205A2 (en) * | 2004-05-13 | 2005-12-01 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 1, group b, member 2 (nr1b2) |
GB0518674D0 (en) * | 2005-09-13 | 2005-10-19 | Oxford Biomedica Ltd | System |
JP6276918B2 (ja) | 2009-11-12 | 2018-02-07 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | 多能性幹細胞を未分化状態で培養する培地、細胞培養および方法 |
WO2020102578A1 (en) * | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc | Compositions and methods for compartment-specific cargo delivery |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4808630A (en) * | 1987-01-16 | 1989-02-28 | United States Of America | Method of treating psychotic illnesses |
EP0812354A2 (de) * | 1995-01-23 | 1997-12-17 | Ligand Pharmaceuticals, Inc. | MENSCHLICHER RETINOID X-GAMMA REZEPTOR (hRXR-GAMMA) |
IT1276459B1 (it) * | 1995-06-30 | 1997-10-31 | Khodor Ammar | Composizioni cosmetiche con proprieta' antimicotiche, efficaci contro la psoriasi e la caduta dei capelli e metodo cosmetico per la |
US5965606A (en) * | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
GB9907461D0 (en) * | 1999-03-31 | 1999-05-26 | King S College London | Neurite regeneration |
JP2002506000A (ja) * | 1997-10-27 | 2002-02-26 | クリエイティブ バイオモレキュールズ, インコーポレイテッド | モルフォゲン活性の増強 |
DK1895010T3 (da) * | 1997-12-22 | 2011-11-21 | Oxford Biomedica Ltd | Vektorer baseret på virus for infektiøs hesteanæmi (eiav) |
EP0943684A3 (de) * | 1998-03-10 | 2002-01-23 | Smithkline Beecham Plc | Frizzled-ähnliche Polypeptide und Polynukleotide |
-
2001
- 2001-03-30 AU AU2001244354A patent/AU2001244354A1/en not_active Abandoned
- 2001-03-30 DE DE60132436T patent/DE60132436T2/de not_active Expired - Fee Related
- 2001-03-30 JP JP2001573009A patent/JP2003533184A/ja not_active Withdrawn
- 2001-03-30 WO PCT/GB2001/001478 patent/WO2001075135A1/en active IP Right Grant
- 2001-03-30 EP EP01917270A patent/EP1268835B1/de not_active Expired - Lifetime
- 2001-03-30 CA CA002399399A patent/CA2399399A1/en not_active Abandoned
- 2001-03-30 AT AT01917270T patent/ATE384133T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2399399A1 (en) | 2001-10-11 |
WO2001075135A1 (en) | 2001-10-11 |
EP1268835B1 (de) | 2008-01-16 |
ATE384133T1 (de) | 2008-02-15 |
EP1268835A1 (de) | 2003-01-02 |
JP2003533184A (ja) | 2003-11-11 |
DE60132436T2 (de) | 2008-04-17 |
DE60132436D1 (de) | 2008-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1595871A3 (de) | Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems | |
CA2366268A1 (en) | Pharmaceutical compositions for cns and other disorders | |
WO1999064059A3 (en) | Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders | |
EP0900568A3 (de) | AMPA Antagonisten zur Behandlung von motorischen Fehlfunktionen verbunden mit Dopaminagonist Therapie | |
IL142768A0 (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
SE9503924D0 (sv) | Novel opioid peptides | |
AU677279B2 (en) | Application of carbamazepine and oxcarbazepine in the treatment of Parkinson's disease and Parkinsonian syndromes | |
AU3126600A (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
GEP20043303B (en) | Polycycloalkylpurines as Adenosine Receptor Antagonists | |
AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
AU3131697A (en) | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders | |
AU1877495A (en) | Naphthylamides as central nervous system agents | |
AU1945795A (en) | Thieno{ 2,3-b}indoles, their preparation and use | |
WO2001010846A3 (en) | 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system | |
NZ332829A (en) | Use of a polypeptide corresponding to a serine threonine kinase receptor, ALK-7 for neurological diseases | |
AU3745795A (en) | Use of CCK-B receptor antagonists for the treatment of sleepdisorders | |
AU2001244354A1 (en) | Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for thetreatment of neurological disorders | |
AU2003255355A1 (en) | Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy | |
AU6428294A (en) | Imidazoloquinoxalinone derivatives as eaa antagonists | |
NZ533358A (en) | 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists | |
AU7439996A (en) | Novel uses of mammalian ctla-8 and related reagents | |
EP0900567A3 (de) | Quinazolin-4-on AMPA Antagonisten zur Behandlung von motorischen Fehlfunktionen verbunden mit Dopaminagonist Therapie | |
WO1994024279A3 (en) | Agents for the prevention and treatment of huntington's disease and other neurological disorders | |
AU8553898A (en) | Use of 2,3-benzodiazepine derivatives for the preparation of pharmaceutical compositions to treat diseases connected with the endogenous opioid system | |
CA2228572A1 (en) | Nk-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy |